Quantum BioPharma (NASDAQ: QNTM) announced the successful completion of a clinical trial demonstrating that its dietary supplement, unbuzzdTM, signi ...
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
In our view, FMC is at risk for a dividend cut. Should FMC not see profit growth in 2025 and 2026 as expected, the dividend may be reduced or cut alltogether. FMC pays a little less than $300 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback